Bloating and functional gastro-intestinal disorders: Where are we and where are we going?

Table 1 Summary of randomised clinical trials specifically assessing bloating reliefs

Agent	Main outcome on bloating symptom	Rome criteria
Probiotics	Bifidobacterium bifidum MIMBb75: Improving bloating/distension[136]	II
	Lactobacillus plantarum 299v: improvement[137]	III
	Multispecies: improvement[138]	III
Symbiotics	Symbiotic mixture: no benefits[115,116]	III
Antibiotics	Rifaximin: reduction in bloating-specific scores[110]	II
	Rifaximin: improvement (39.5% vs 28.7%)[112]	II
Prokinetics	Tegaserod: improvement[120]	I
	Tegaserod: improvement[139-141]	II
	Tegaserod: no differences vs placebo[142]	II
	Prucalopride: improvement[126]	II
Antispasmodic	Otilonium bromide improvement[143]	II
	Mebeverine vs Otilonium bromide: improvement significantly achieved by both treatments[144]	II
Antidepressant	Paroxetine: no difference vs placebo[145]	I
	Citalopram: improvement[146]	II
	Fluoxetine: improvement[147]	II